# A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv

Source: https://onco.cc/trials/nct06962865/  
OnCo record `nct06962865` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC is a phase 2 interventional study registered as NCT06962865 by RemeGen Co., Ltd., with 80 participants planned, started 2025-06-30 and due to reach its primary completion in 2026-05-31. Interventions recorded: RC108, Furmonertinib Mesilate Tablets Monotherapy. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06962865
- Phase: 2
- Setting: A Randomized, Open, Controlled, Multicenter Phase II Clinical Study of RC108 in Combination With Furmonertinib Versus Furmonertinib for the First-Line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06962865: https://clinicaltrials.gov/study/NCT06962865

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06962865.json